In patients with BML in the medial compartment at baseline , the BML score at 36months was decreased in both treatment groups compared with the placebo group ( SrRan 1g/day , p = 0.002 and SrRan 2g/day p = 0.001 , respectively ) , and CVL significantly decreased with SrRan 2g/day ( p = 0.023 ) in the plateau compared with placebo .